Slingshot members are tracking this event:
Grazoprevir/Elbasvir for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection Company Granted FDA Priority Review with Target Action Date of January 28, 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Jan 28, 2016
- Understanding the impact of Merck's ZEPATIER on the HCV market as it now competes with HARVONI and Viekira Pak GILD, MRK, ABBV Executed On: Feb 05, 2016 at 10:00 AM EST
Related Keywords Grazoprevir, Elbasvir, Chronic Hepatitis C